American Society for Radiation Oncology (ASTRO) shared on X:
“News from ASTRO26: Real-world data indicate lower adherence rates for breast cancer endocrine therapy when radiation therapy is omitted.
Nationwide insurance claims analysis finds fewer than 30% of patients remained adherent for five years after lumpectomy.
As seen in Inside Precision Medicine, AuntMinnie.org, HealthDay News, Cure today and more. Presented by Shannon Jiang.”
Jose G. Bazan, Chair of the ASTRO Breast Cancer Resource Panel and a Radiation Oncologist at City of Hope Comprehensive Cancer Center in Duarte, said:
‘Radiation therapy omission can be appropriate for selected people with lower-risk breast cancer, but endocrine therapy is an important part of that strategy. This study adds real-world context to treatment discussions by showing how difficult long-term adherence can be. When discussing omission, clinicians should consider radiation’s established local-control benefit alongside the practical realities of staying on endocrine therapy for years. The goal is to choose a treatment plan that patients can realistically maintain over time.’
Proceed to the video attached to the post.
You may also be interested in: FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy
